The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Shares of US clinical-stage biotech Allogene Therapeutics rocketed 41% to $1.99 on Friday, as it announced the publication of ...

That growth came after the facility received approval from the European Medicines Agency to commercially produce allogeneic cell therapy drug products, which the company said was a first for a ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Completion of enrollment and dosing in the low dose cohort of the CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial, marking a significant step in clinical development for treating ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Losing around 50 to 100 hair strands in a day should not get you overly concerned. However, seeing more scalp than hair is ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

Patients with childhood and young adult cancer have an increased long-term risk for diabetes, noted as early as 10 years ...